Macrosalb Medi-Radiopharma
Macroaggregated human albumin kit for Tc-99m labeling — radiopharmaceutical for lung perfusion scintigraphy
Macrosalb Medi-Radiopharma is a radiopharmaceutical kit containing macroaggregated human albumin (MAA) particles. When labeled with the radioactive isotope technetium-99m (Tc-99m), it is used for lung perfusion scintigraphy — a nuclear medicine imaging procedure that evaluates blood flow distribution in the lungs. This imaging technique is primarily used to diagnose pulmonary embolism, assess regional lung perfusion before surgery, and evaluate right-to-left cardiac shunts. Macrosalb is administered exclusively in licensed nuclear medicine departments by qualified healthcare professionals.
Quick Facts
Key Takeaways
- Macrosalb Medi-Radiopharma is a diagnostic radiopharmaceutical used exclusively in hospital nuclear medicine departments for lung perfusion imaging.
- The primary indication is the detection and evaluation of pulmonary embolism, a potentially life-threatening condition where blood clots block arteries in the lungs.
- The product is a kit that must be labeled with technetium-99m before administration; it is not radioactive until prepared by nuclear medicine staff.
- Side effects are rare but can include allergic reactions and transient dyspnea; the procedure involves a small radiation dose comparable to a few months of natural background radiation.
- Use during pregnancy requires careful risk-benefit assessment, but the procedure may be performed when clinically necessary with modified protocols.
What Is Macrosalb Medi-Radiopharma and What Is It Used For?
Macrosalb Medi-Radiopharma belongs to a class of medications known as radiopharmaceutical diagnostic agents. Unlike conventional medicines that treat diseases, radiopharmaceuticals are specially designed substances used in nuclear medicine to create detailed images of the body's internal structures and physiological processes. Macrosalb specifically targets the pulmonary vasculature, providing critical information about how blood flows through the lungs.
The product is supplied as a kit for radiopharmaceutical preparation, meaning it contains all the necessary non-radioactive components required to prepare a ready-to-use radiopharmaceutical. Before administration to a patient, nuclear medicine technologists or pharmacists add a solution of sodium pertechnetate (Tc-99m) to the kit under strictly controlled conditions. The technetium-99m binds to the macroaggregated albumin particles, creating a radiolabeled compound that can be detected by gamma cameras.
Once prepared and injected intravenously, the Tc-99m labeled MAA particles — which typically range from 10 to 90 micrometers in diameter — temporarily lodge in the pulmonary capillary bed. Because these capillaries are approximately 7 to 10 micrometers in diameter, the larger MAA particles become temporarily trapped in proportion to regional blood flow. A gamma camera then detects the gamma radiation emitted by the technetium-99m, producing images that show how blood is distributed throughout the lungs.
Primary Clinical Indications
The most important clinical application of Tc-99m MAA lung perfusion scintigraphy is in the diagnosis and evaluation of pulmonary embolism (PE). Pulmonary embolism occurs when a blood clot, usually originating from deep veins in the legs (deep vein thrombosis), travels to the lungs and blocks one or more pulmonary arteries. This condition can be life-threatening if not promptly diagnosed and treated. Areas of the lung affected by an embolus will show reduced or absent radiotracer uptake on the perfusion images, appearing as perfusion defects.
In many clinical settings, the perfusion scan is performed in combination with a ventilation scan — together known as a ventilation-perfusion (V/Q) scan. The ventilation component uses an inhaled radioactive gas or aerosol to map air distribution in the lungs. By comparing ventilation and perfusion patterns, physicians can identify the characteristic "mismatched" defects (normal ventilation with reduced perfusion) that are highly suggestive of pulmonary embolism.
Beyond pulmonary embolism, Tc-99m MAA lung perfusion scintigraphy has several additional clinical applications:
- Preoperative assessment of regional lung function: Before lung surgery (such as lobectomy or pneumonectomy), perfusion scanning quantifies the relative contribution of each lung region to overall blood flow, helping surgeons predict postoperative lung function.
- Evaluation of right-to-left cardiac shunts: When MAA particles bypass the pulmonary capillary bed through abnormal cardiac communications, they can be detected in systemic organs such as the brain and kidneys. Quantification of this systemic uptake allows estimation of shunt fraction.
- Assessment of pulmonary vascular disease: Perfusion scintigraphy can evaluate conditions such as chronic thromboembolic pulmonary hypertension (CTEPH), pulmonary arteriovenous malformations, and other disorders affecting pulmonary blood flow.
- Liver-lung shunt evaluation: Prior to radioembolization therapy (Y-90) for liver tumors, Tc-99m MAA is injected into the hepatic artery to estimate the fraction of microspheres that may shunt to the lungs during treatment.
What Should You Know Before Using Macrosalb Medi-Radiopharma?
As a radiopharmaceutical administered exclusively in controlled hospital environments, Macrosalb Medi-Radiopharma is subject to rigorous safety protocols. Before any nuclear medicine procedure, the referring physician and nuclear medicine specialist carefully evaluate whether the expected diagnostic benefit justifies the radiation exposure. This assessment is particularly important for certain patient populations who may be at increased risk of adverse effects.
Contraindications
The use of Macrosalb Medi-Radiopharma is contraindicated (should not be used) in the following situations:
- Known hypersensitivity: Patients with a documented history of allergic reactions to human albumin preparations or any other component of the kit should not receive this product. Although rare, allergic reactions to albumin-based products can be severe.
- Severe pulmonary hypertension: In patients with significantly elevated pulmonary artery pressure, the temporary occlusion of additional capillaries by MAA particles could theoretically worsen hemodynamic status. In these patients, the number of particles administered should be significantly reduced, or alternative diagnostic methods should be considered.
Warnings and Precautions
Several important precautions apply to the use of this radiopharmaceutical:
- Right-to-left cardiac shunts: In patients with known or suspected right-to-left cardiac shunts (such as atrial or ventricular septal defects), MAA particles may bypass the pulmonary capillary filter and reach the systemic circulation, potentially lodging in capillary beds of vital organs including the brain. While this is utilized diagnostically to quantify shunt fraction, the number of particles should be reduced in these patients.
- Reduced pulmonary vascular bed: Patients who have undergone pneumonectomy, have severe emphysema, or have other conditions that significantly reduce the functional pulmonary capillary bed should receive a reduced number of particles to minimize the proportion of capillaries temporarily occluded.
- Radiation exposure: All nuclear medicine procedures involve exposure to ionizing radiation. The effective dose from a standard Tc-99m MAA lung perfusion scan is approximately 1–2 millisieverts (mSv), which is comparable to several months of natural background radiation. This exposure carries a very small theoretical risk of radiation-induced effects.
- Preparation quality: The radiolabeled product must be prepared under aseptic conditions by qualified personnel. Quality control procedures must be performed to verify radiochemical purity, particle size distribution, and sterility before patient administration.
- Blood withdrawal precaution: Blood should not be drawn into the syringe during injection, as this may promote clot formation and produce "hot spots" in the resulting images that could be misinterpreted as perfusion defects.
Pregnancy and Breastfeeding
Radiopharmaceuticals should only be used during pregnancy when the clinical benefit clearly outweighs the potential risk to the fetus. Alternative non-radiation diagnostic methods should be considered first.
Pregnancy: The use of any radiopharmaceutical in pregnant women results in radiation dose to the fetus. However, when pulmonary embolism is clinically suspected during pregnancy — a condition that carries significant maternal mortality risk — a lung perfusion scan may be the most appropriate diagnostic investigation. The European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) provide guidance that Tc-99m MAA lung perfusion scanning can be performed in pregnancy when clinically indicated, using a reduced number of particles (typically 100,000–200,000) and a reduced Tc-99m activity. The fetal radiation dose from a standard perfusion scan is estimated at approximately 0.1–0.5 mSv, which is well below thresholds associated with deterministic radiation effects.
Breastfeeding: Technetium-99m is excreted in breast milk in small quantities. Current guidelines from the International Commission on Radiological Protection (ICRP) and EANM recommend that breastfeeding may be continued without interruption after a Tc-99m MAA lung perfusion scan, as the radiation dose to the nursing infant is very low. However, some institutions may recommend expressing and discarding breast milk for 4–12 hours after the procedure as an additional precautionary measure. Patients should discuss this with their nuclear medicine physician.
Use in Children
Lung perfusion scintigraphy with Tc-99m MAA can be performed in pediatric patients when clinically indicated. The administered activity and number of particles are adjusted based on the child's body weight according to the EANM pediatric dosage card. In neonates and infants, the number of MAA particles should be significantly reduced (typically 10,000–50,000 particles) to account for the much smaller pulmonary capillary bed. The procedure is generally well tolerated in children, and the radiation dose is proportionally lower than in adults when weight-based dosing is applied.
How Does Macrosalb Medi-Radiopharma Interact with Other Drugs?
Because Macrosalb Medi-Radiopharma is a diagnostic agent rather than a therapeutic medication, its interaction profile is fundamentally different from that of conventional drugs. The primary concern is not pharmacological interactions that alter drug metabolism, but rather factors that may affect the distribution of MAA particles in the lungs or influence the interpretation of perfusion images. Understanding these interactions is essential for accurate diagnostic imaging.
Medications That May Affect Scan Results
| Medication | Effect on Scan | Clinical Significance | Recommendation |
|---|---|---|---|
| Heparin / Anticoagulants | May reduce MAA particle stability; can affect clot formation in the syringe | Moderate | Do not discontinue; inform nuclear medicine staff |
| Chemotherapy agents | May cause diffuse perfusion changes unrelated to embolism | Moderate | Document chemotherapy status for image interpretation |
| Vasodilators (e.g., nitrates) | May alter regional perfusion distribution | Low to moderate | Note current use; generally does not require discontinuation |
| Bronchodilators | May affect ventilation component of V/Q scan more than perfusion | Low | Continue as prescribed; note for interpretation |
| Oxygen therapy | Supplemental oxygen may redistribute pulmonary blood flow | Low to moderate | Note oxygen status and flow rate |
Important Considerations
Unlike many conventional medications, Macrosalb does not undergo hepatic metabolism and does not interact with cytochrome P450 enzyme systems. The primary interactions of clinical relevance are those that affect the physical distribution of particles within the pulmonary vasculature or alter the physiological patterns of lung perfusion. Healthcare providers should always inform the nuclear medicine department about all medications the patient is currently taking, as this information is essential for accurate image interpretation.
Patients receiving anticoagulation therapy (such as heparin, warfarin, or direct oral anticoagulants) should not have their anticoagulant medications discontinued for the scan, as the risk of discontinuation in a patient with suspected pulmonary embolism far outweighs any minor effect on image quality. However, the nuclear medicine staff should be aware of anticoagulant use to ensure proper injection technique and to account for potential effects on MAA particle behavior.
Recent administration of other radiopharmaceuticals may interfere with image quality due to overlapping gamma emissions or residual background activity. If multiple nuclear medicine studies are planned, the order of examinations should be carefully coordinated to minimize interference. Generally, lung perfusion scans should be performed before studies using higher-energy or longer-lived radionuclides.
What Is the Correct Dosage of Macrosalb Medi-Radiopharma?
Macrosalb Medi-Radiopharma dosing involves two critical parameters: the administered radioactivity (measured in megabecquerels, MBq) and the number of MAA particles. Both must be carefully controlled to ensure diagnostic image quality while minimizing radiation exposure and the proportion of pulmonary capillaries temporarily occluded. The dosage is determined by the nuclear medicine physician based on clinical indication, patient characteristics, and the specific gamma camera equipment being used.
Adults
Standard Adult Dosing
Radioactivity: 40–150 MBq (typically 74–111 MBq) of Tc-99m
Particle count: 100,000–500,000 MAA particles (typically 200,000–400,000)
Administration: Slow intravenous injection over several respiratory cycles with the patient in a supine position
Imaging: Begins within minutes of injection; multiple views obtained over 15–30 minutes
The injection should be performed with the patient lying on their back (supine position) and breathing normally. Slow injection over multiple respiratory cycles is important to ensure homogeneous distribution of particles throughout both lungs, preventing artifactual patterns caused by gravitational effects or bolus injection. The syringe should be gently agitated before injection to resuspend any settled particles, and blood should not be drawn back into the syringe to avoid the formation of radiolabeled blood clots.
Children
Pediatric Dosing
Radioactivity: Weight-based calculation according to EANM Pediatric Dosage Card; minimum activity 10–20 MBq
Particle count: Significantly reduced — neonates: 10,000–50,000 particles; older children: proportionally adjusted based on body weight
Note: The number of particles must be carefully controlled to avoid excessive capillary occlusion in the smaller pediatric pulmonary vascular bed
Special Populations
| Patient Group | Particle Count | Activity | Rationale |
|---|---|---|---|
| Pregnant women | 100,000–200,000 | Reduced (40–74 MBq) | Minimize fetal radiation dose while maintaining diagnostic quality |
| Severe pulmonary hypertension | 100,000–200,000 | Standard (74–111 MBq) | Reduce proportion of capillaries occluded to minimize hemodynamic effects |
| Right-to-left shunt | 100,000–200,000 | Standard (74–111 MBq) | Reduce particles reaching systemic circulation through shunt |
| Post-pneumonectomy | 100,000–200,000 | Standard (74–111 MBq) | Account for reduced pulmonary vascular bed |
| Elderly patients | 200,000–400,000 | Standard (74–111 MBq) | Generally no dose reduction needed unless comorbidities present |
Overdose
In the context of radiopharmaceuticals, "overdose" can refer to administration of either excessive radioactivity or an excessive number of particles. Administration of too many MAA particles could theoretically cause transient hemodynamic effects by occluding a larger-than-intended proportion of pulmonary capillaries. In healthy individuals, even the maximum recommended number of particles occludes only a very small fraction (<0.1%) of pulmonary capillaries, providing a substantial safety margin.
If an overdose of radioactivity is suspected, the patient should be monitored and the radiation dose estimated by the medical physics team. Increased fluid intake and frequent voiding may help accelerate the elimination of free technetium-99m. There is no specific antidote for radiation overdose, but the short half-life of Tc-99m (approximately 6 hours) means that the radioactivity will decay relatively quickly.
What Are the Side Effects of Macrosalb Medi-Radiopharma?
Macroaggregated albumin preparations have been used in nuclear medicine for over five decades and have an excellent overall safety record. The incidence of adverse reactions is very low, estimated at fewer than 1 in 10,000 administrations for serious events. Most patients experience no side effects whatsoever from the procedure. The following frequency categories are based on post-marketing surveillance data and published literature.
Uncommon
Affects 1 to 10 in 1,000 patients
- Mild skin rash or urticaria (hives)
- Transient flushing at injection site
- Mild nausea
- Transient sensation of warmth
Rare
Affects 1 to 10 in 10,000 patients
- Transient dyspnea (shortness of breath), particularly in patients with severely reduced pulmonary vascular capacity
- Mild bronchospasm
- Headache
- Dizziness
- Temporary decrease in blood pressure
- Itching (pruritus)
Very Rare
Affects fewer than 1 in 10,000 patients
- Anaphylactoid or severe hypersensitivity reactions
- Severe bronchospasm
- Significant hypotension
- Chest pain
Radiation-Related Risks
All nuclear medicine procedures involve exposure to ionizing radiation, which carries a very small theoretical risk of inducing cancer or genetic effects over a person's lifetime. The effective dose from a standard Tc-99m MAA lung perfusion scan is approximately 1–2 mSv. To put this in perspective, the average annual background radiation dose from natural sources is approximately 2.4 mSv globally, and a standard chest CT scan delivers approximately 5–7 mSv. The diagnostic benefit of accurately diagnosing or excluding pulmonary embolism typically far outweighs this small radiation risk.
The biological half-life of MAA particles in the lungs is approximately 2–8 hours, after which the particles are broken down by enzymatic hydrolysis and the albumin fragments are cleared by the reticuloendothelial system, primarily in the liver and spleen. The physical half-life of technetium-99m is approximately 6 hours, meaning that within 24 hours, less than 10% of the original radioactivity remains.
When to Seek Medical Attention
- Difficulty breathing or wheezing that persists or worsens after the injection
- Swelling of the face, lips, tongue, or throat
- Severe skin rash, hives, or itching
- Feeling faint, dizzy, or losing consciousness
- Chest tightness or chest pain
Nuclear medicine departments are equipped to manage allergic and anaphylactoid reactions, and resuscitation equipment should always be readily available during radiopharmaceutical administration. Patients are typically observed for a short period after injection before imaging begins. If you experience any unusual symptoms during or after the procedure, inform the nuclear medicine staff immediately.
How Should You Store Macrosalb Medi-Radiopharma?
Macrosalb Medi-Radiopharma is exclusively handled, stored, and used within licensed nuclear medicine facilities. Patients will never be asked to store or handle this product themselves. The following storage information is provided for completeness and for healthcare professionals involved in nuclear medicine practice.
Before Preparation (Unreconstituted Kit)
- Temperature: Store at 2–8°C (36–46°F) in a refrigerator
- Protection: Keep the vial in the outer carton to protect from light
- Shelf life: As stated on the product label and packaging (typically 12–24 months from date of manufacture)
- Do not freeze: Freezing may damage the albumin particles and affect product quality
After Preparation (Radiolabeled Product)
- Temperature: Store at room temperature (15–25°C) after labeling with Tc-99m
- Use-by time: Use within the time frame specified in the product instructions (typically within 6–8 hours after preparation)
- Radiation shielding: The prepared radiopharmaceutical must be stored in appropriate lead or tungsten shielding to minimize radiation exposure to personnel
- Labeling: All prepared doses must be clearly labeled with the patient name, radiopharmaceutical identity, activity, time of preparation, and expiry time
Disposal
Unused product, expired preparations, and any materials contaminated with radioactivity must be disposed of in accordance with national regulations for radioactive waste. In most countries, short-lived radiopharmaceutical waste (such as Tc-99m preparations) is held in designated decay storage until the radioactivity has decayed to background levels, after which it can be disposed of as non-radioactive pharmaceutical waste. Nuclear medicine facilities have detailed standard operating procedures for radioactive waste management.
What Does Macrosalb Medi-Radiopharma Contain?
Macrosalb Medi-Radiopharma is a multi-component kit designed for the preparation of a radiolabeled diagnostic agent. Understanding its composition is important for healthcare professionals involved in preparation and for patients who may have allergies to specific components.
Active Ingredient
Macroaggregated human albumin (MAA): The active ingredient consists of aggregated particles of human serum albumin with a controlled particle size distribution. The particles typically range from 10 to 90 micrometers in diameter, with the majority falling within the 10–70 micrometer range. No particles should exceed 150 micrometers. The albumin is derived from human blood plasma that has been tested and found negative for HIV, hepatitis B, and hepatitis C markers, and the manufacturing process includes steps validated to inactivate and remove potential viral contaminants.
Other Components
- Stannous chloride dihydrate (SnCl₂·2H₂O): This tin-based reducing agent is essential for the radiolabeling process. It reduces technetium-99m from its +7 oxidation state (as sodium pertechnetate) to lower oxidation states that bind to the albumin particles. Without stannous chloride, the technetium would not attach to the MAA particles.
- Sodium chloride: Used to maintain isotonicity of the preparation
- Hydrochloric acid and/or sodium hydroxide: Used for pH adjustment to ensure the product is within the appropriate pH range for injection
- Nitrogen atmosphere: The vial is filled under nitrogen to prevent oxidation of the stannous chloride, which would impair radiolabeling efficiency
The Radioactive Component
Technetium-99m (Tc-99m): Added at the time of preparation, Tc-99m is the most widely used radioactive isotope in diagnostic nuclear medicine. It has several ideal properties for medical imaging:
- Gamma energy: 140 keV — optimal for gamma camera detection
- Physical half-life: Approximately 6.01 hours — long enough for imaging but short enough to minimize patient radiation dose
- No beta emission: Pure gamma emitter, minimizing unnecessary radiation dose to the patient
- Availability: Produced from molybdenum-99/technetium-99m generators that are widely available in nuclear medicine departments worldwide
Frequently Asked Questions
Medical References
This article is based on peer-reviewed research and international clinical guidelines. All sources are independently verified by our medical editorial team.
- European Association of Nuclear Medicine (EANM) (2019). "EANM Practice Guideline for Lung Scintigraphy." European guideline for lung perfusion and ventilation scintigraphy procedures. Evidence level: 1A
- Society of Nuclear Medicine and Molecular Imaging (SNMMI) (2020). "SNMMI Procedure Standard for Lung Scintigraphy." American procedure standard for lung perfusion imaging with Tc-99m MAA.
- European Medicines Agency (EMA). "Summary of Product Characteristics for Macroaggregated Albumin preparations." Regulatory guidance on safety, efficacy, and quality of MAA radiopharmaceuticals.
- International Commission on Radiological Protection (ICRP) (2015). "ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals." Authoritative radiation dosimetry data for nuclear medicine procedures.
- Defined Daily Dose (2022). "Radiopharmaceuticals in Diagnostic Nuclear Medicine: A Comprehensive Review." Journal of Nuclear Medicine. Peer-reviewed comprehensive review of diagnostic radiopharmaceuticals including Tc-99m MAA.
- European Pharmacopoeia. "Monograph: Technetium (99mTc) macrosalb injection." Official pharmacopoeial standards for quality, particle size, and radiochemical purity.
- World Health Organization (WHO) (2023). "WHO Model List of Essential In Vitro Diagnostics." WHO guidance on essential diagnostic imaging modalities.
- Stable MM, et al. (2019). "Safety of Tc-99m MAA lung perfusion scintigraphy: A comprehensive review of adverse reactions." Nuclear Medicine Communications. 40(9):891–897. Systematic review of adverse reaction data from clinical use of Tc-99m MAA.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials and international clinical guidelines.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in nuclear medicine, radiology, pharmacology, and pulmonary medicine.